secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kezar Life Sciences, Inc. (KZR)
CIK:        0001645666
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001645666-25-000036
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kezar Life Sciences Q2 net loss $13.7M; FDA lifts partial hold on AIH trial
---------------------------------------------------------------------------

- Net loss $13.7M ($1.87/share) vs $21.5M loss in Q2 2024; R&D expenses down 41% to $9.6M.
- Cash, equivalents & marketable securities $100.8M as of June 30, 2025 ($132.2M at Dec 31, 2024).
- FDA removed partial clinical hold on PORTOLA Phase 2a trial for zetomipzomib in autoimmune hepatitis.
- Submitted Type C meeting request to FDA for Q4 2025 to discuss registration-enabling AIH study design.
- PORTOLA Phase 2a data selected for oral presentation at The Liver Meeting 2025 (Nov 7-11).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645666/000164566625000036/0001645666-25-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645666/000164566625000036/kzr-20250813.htm
  HTML page:      https://secwatch.observer/filing/0001645666-25-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer